CDK7

Cyclin-dependent kinase 7

172,525 patent compounds predicted against CDK7, 117,959 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL147483	0.62	16/20
SCHEMBL150384	0.76	15/20
SCHEMBL146998	0.57	15/20
SCHEMBL145013	0.56	15/20
SCHEMBL145120	0.55	15/20
SCHEMBL146834	0.64	12/20
SCHEMBL144081	0.59	11/20
SCHEMBL84411	0.50	11/20
Seliciclib (SCHEMBL94728)	1.00	6/20
(Rs)-Roscovitine (SCHEMBL172593)	1.00	6/20
SCHEMBL144879	0.38	5/20
SCHEMBL145136	0.38	5/20
SCHEMBL39693	0.35	5/20
SCHEMBL21498	0.33	5/20
SCHEMBL147422	0.66	4/20
SCHEMBL144979	0.56	4/20
SCHEMBL148271	0.47	4/20
SCHEMBL14637	0.37	4/20
SCHEMBL172475	0.36	4/20
Alvocidib (SCHEMBL3651)	1.00	3/20

Germline variants in CDK7 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full CDK7 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to CDK7 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer	PHASE4	NOT_YET_RECRUITING
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)	PHASE3	COMPLETED
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study	PHASE3	RECRUITING
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer	PHASE3	ACTIVE_NOT_RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression	PHASE2	COMPLETED
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy	PHASE2	COMPLETED
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6	PHASE2	RECRUITING
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)	PHASE1/PHASE2	RECRUITING
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC	PHASE2	ACTIVE_NOT_RECRUITING
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer	PHASE2	RECRUITING
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer	PHASE2	COMPLETED
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors	PHASE1/PHASE2	COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma	PHASE1/PHASE2	RECRUITING
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer	PHASE2	WITHDRAWN
Abemaciclib + Pembrolizumab In Glioblastoma	PHASE2	WITHDRAWN
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma	PHASE1	COMPLETED
A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy	PHASE1	NOT_YET_RECRUITING
A Study of PRT2527 in Participants With Advanced Solid Tumors	PHASE1	COMPLETED
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer	PHASE1	NOT_YET_RECRUITING
Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)	PHASE1	COMPLETED
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy	PHASE1	RECRUITING
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period	nan	UNKNOWN
The SONImage Study	nan	ACTIVE_NOT_RECRUITING
Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy	nan	COMPLETED
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CDK7 binder may also engage these)

Protein	Name	Similarity
Q03147	—	1.000	Q03147 →
P51952	—	1.000	P51952 →
P20911	—	0.998	P20911 →
G5EFV5	—	0.997	G5EFV5 →
A8WIP6	—	0.995	A8WIP6 →
P51953	—	0.994	P51953 →
Q5R7I7	—	0.993	Q5R7I7 →
Q64261	—	0.993	Q64261 →
Q12126	—	0.993	Q12126 →
Q9C9M7	—	0.993	Q9C9M7 →
P17157	—	0.992	P17157 →
Q8SW92	—	0.992	Q8SW92 →
O60145	—	0.992	O60145 →
Q9C9U2	—	0.992	Q9C9U2 →
Q9WTY9	—	0.991	Q9WTY9 →
Q6AXJ9	—	0.990	Q6AXJ9 →
P51166	—	0.990	P51166 →
Q6FKD4	—	0.990	Q6FKD4 →
CDK20	Cyclin-dependent kinase 20	0.990	landscape →
Q38775	—	0.990	Q38775 →
Q0J4I1	—	0.989	Q0J4I1 →
Q92241	—	0.989	Q92241 →
Q8LG64	—	0.989	Q8LG64 →
Q9LMT0	—	0.989	Q9LMT0 →
Q8LF80	—	0.989	Q8LF80 →
Q9JHU3	—	0.988	Q9JHU3 →
P14681	—	0.988	P14681 →
P25859	—	0.988	P25859 →
Q91727	—	0.988	Q91727 →
MAPK13	Mitogen-activated protein kinase 13	0.988	landscape →